Alnylam Pharmaceuticals Inc. is seeing a positive uptick in its stock price, driven by promising developments in Alzheimer's treatment.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is rising today, with shares up 1.26% to close at CA$252.74. This increase comes amid growing interest in the company's innovative approaches to treating Alzheimer's disease, particularly as the industry observes World Alzheimer's Day.
Investor takeaway: Investors are encouraged by Alnylam's advancements in RNA interference therapies, particularly its promising pipeline targeting Alzheimer's disease, which could enhance its market position.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$32.99B
P/E
43.9x
52W high
$495.55
52W low
$197.81
1W change
+1.66%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 48.8% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+48.8% Upside
Current Price
C$249.59
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.7%
Annualized
90-Day Vol
77.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$208.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$235.17 | C$200.86 – C$275.34 |
| 60 trading days | C$221.58 | C$177.28 – C$276.94 |
| 90 trading days | C$208.77 | C$158.87 – C$274.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.26% Increase in Stock Price
Alnylam's stock price rose by 1.26%, reflecting positive market sentiment driven by its Alzheimer's research initiatives.
Bull case
Alnylam's mivelsiran therapy has shown potential in lowering amyloid precursor protein levels, which play a crucial role in Alzheimer's progression. With the growing global focus on Alzheimer's treatments, Alnylam's innovative pipeline puts it in a strong position for future growth.
Bear case
Despite its advancements, Alnylam faces tough competition in the Alzheimer's space. The success of its therapies will depend on the outcomes of clinical trials and regulatory approvals.
Advertisement
Alnylam's Innovative Pipeline
Alnylam is advancing mivelsiran, an experimental RNAi therapy designed to lower amyloid precursor protein levels, potentially reducing amyloid-beta formation in the brain. Recent phase I data has shown promising results, leading to the start of phase II trials in patients with Down syndrome-associated Alzheimer's disease.
Market Context and Future Prospects
The global RNA interference therapeutics market is projected to grow significantly, reaching USD 31.4 billion by 2035. Alnylam's focus on rare and chronic diseases positions it well within this expanding market, especially as regulatory support for innovative therapies continues to strengthen.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
